ArticleMolecules (Basel, Switzerland)2021
Curcumin Loaded Dendrimers Specifically Reduce Viability of Glioblastoma Cell Lines.
Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 63 citations in OpenAlex.
- Mitochondria-Targeted Nanotherapies in Aging Neurodegenerative Disorders: Emerging Prospects and Clinical Potential.Advanced healthcare materials · 2026Review
- PAMAM dendrimers as efficient drug nanocarriers of natural compounds in breast cancer therapeutics.Frontiers in oncology · 2026Review
- Curcumin-based biocompatible nanocarriers: a contemporary perspective in functional foods and biomedical applications.Discover nano · 2025Review
- Oxidative Stress and Antioxidants in Glioblastoma: Mechanisms of Action, Therapeutic Effects and Future Directions.Antioxidants (Basel, Switzerland) · 2025Review
- Cancer chemoprevention: signaling pathways and strategic approaches.Signal transduction and targeted therapy · 2025Review
- Potential of Curcumin and Its Analogs in Glioblastoma Therapy.Antioxidants (Basel, Switzerland) · 2025Review
- GCN5-targeted dual-modal probe across the blood-brain barrier for borders display in invasive glioblastoma.Nature communications · 2025Article
- Curcumin-Based Nanoparticles: Advancements and Challenges in Tumor Therapy.Pharmaceutics · 2025Review
- Innovative nanoparticle-based therapeutic strategies against glioblastoma multiform: a focus on enhanced delivery systems and efficacy.Frontiers in bioengineering and biotechnology · 2025Review
- Review
- A Review on Current Aspects of Curcumin-Based Effects in Relation to Neurodegenerative, Neuroinflammatory and Cerebrovascular Diseases.Molecules (Basel, Switzerland) · 2024Review
- Targeting the undruggable in glioblastoma using nano-based intracellular drug delivery.Medical oncology (Northwood, London, England) · 2024Review
- Natural compounds-based nanomedicines for cancer treatment: Future directions and challenges.Drug delivery and translational research · 2024Review
- Curcumin nanoparticles in heat stroke management.Journal of nanobiotechnology · 2024Article
- Current Non-Metal Nanoparticle-Based Therapeutic Approaches for Glioblastoma Treatment.Biomedicines · 2024Review
- Advances in Nanocarrier Systems for Overcoming Formulation Challenges of Curcumin: Current Insights.Nanomaterials (Basel, Switzerland) · 2024Review
- Curcumin-Conjugated PAMAM Dendrimers of Two Generations: Comparative Analysis of Physiochemical Properties Using Adriatic Topological Indices.ACS omega · 2024Article
- The Nanotech Potential of Curcumin in Pharmaceuticals: An Overview.Current drug discovery technologies · 2024Review
- Advances of curcumin in nervous system diseases: the effect of regulating oxidative stress and clinical studies.Frontiers in pharmacology · 2024Review
- Curcumin encapsulated in PAMAM dendrimers for the therapeutic treatment of ischemic stroke in rats.Frontiers in cell and developmental biology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 1 country.
Funding
Abstract
Glioblastoma (GB) is a deadly and aggressive cancer of the CNS. Even with extensive resection and chemoradiotherapy, patient survival is still only 15 months. To maintain growth and proliferation, cancer cells require a high oxidative state. Curcumin, a well-known anti-inflammatory antioxidant, is a potential candidate for treatment of GB. To facilitate efficient delivery of therapeutic doses of curcumin into cells, we encapsulated the drug in surface-modified polyamidoamine (PAMAM) dendrimers. We studied the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.